Healthcare Industry News:  Melanoma test 

Diagnostics Oncology Reimbursement

 News Release - July 13, 2017

DermTech Secures Billing Codes for its Proprietary Melanoma Test

LA JOLLA, Calif., July 13, 2017 -- (Healthcare Sales & Marketing Network) -- DermTech, Inc., the global leader in non-invasive molecular dermatology, reported today that the American Medical Association (AMA) has granted the company Category 1, Tier 2 Molecular Pathology procedure codes related to its proprietary test for the detection of melanoma related gene expression. The company has secured this Common Procedural Terminology (CPT) coding for LINC and PRAME, the two primary genes included in the pigmented lesion assay, the company's non-invasive biopsy and gene expression test for skin cancer. These genes will be added to the approved list for CPT code 81401, as maintained by the American Medical Association, and published July 1, 2017. The application was supported by multiple clinical studies demonstrating the clinical validity and utility of the test as well as support from key dermatology societies including the American Academy of Dermatology.

John Dobak, M.D., Chief Executive Officer of DermTech, commented, "We are very pleased to have achieved this important milestone for the Company. I am extremely proud of the entire DermTech team who worked tirelessly to create our gene expression platform technology and secure coding for the pigmented lesion assay. We thank the AMA, the American Academy of Dermatology, the College of American Pathologists, the Society for Investigative Dermatology, and others that unanimously supported our application. Our goal continues to be providing world class non-invasive molecular pathology directly to the dermatologist to improve patient care".

About DermTech

DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit:

Source: DermTech

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.